Skip to main content

Want a detailed portfolio tracker?

ProPhase Labs (PRPH) EBITDA (2010 - 2025)

ProPhase Labs (PRPH) EBITDA from Jun 30, 2010 to Sep 30, 2025. The TTM ProPhase Labs (PRPH) EBITDA is -$25M. You can adjust inflation or export chart.

All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.

Annual EBITDA

Quarterly EBITDA

ProPhase Labs (PRPH) EBITDA CAGR table

PeriodCAGR
1 Year TTM-4.12%
5 Years TTM+73.15%
10 Years TTM+24.74%
All Time TTM+25.75%

Annual EBITDA change of ProPhase Labs (PRPH)

YearEBITDAChange
2025-$9.13M-71.86%
2024-$32M+113.84%
2023-$15M-153.59%
2022$28M+117.10%
2021$13M-900.00%
2020-$1.63M-42.61%
2019-$2.84M+127.20%
2018-$1.25M-65.75%
2017-$3.65M+63.68%
2016-$2.23M-30.75%
2015-$3.22M-57.35%
2014-$7.55M-1243.94%
2013$660K-177.65%
2012-$850K-64.29%
2011-$2.38M-26.32%
2010-$3.23M-5.28%
2009-$3.41MN/A

Comparison ProPhase Labs (PRPH) five years EBITDA CAGR with competitors

ProPhase Labs (PRPH) five years EBITDA CAGR is 73.15%.

TickerNamefive years EBITDA CAGRUpside
MEDPMedpace Holdings Inc25.16%-65.61%
ISPCiSpecimen Inc25.14%-65.64%
PSNLPersonalis Inc18.83%-74.26%
WATWaters Corp17.45%-76.14%
BNRBurning Rock Biotech Ltd17.26%-76.40%
ICLRIcon Plc12.53%-82.87%
IDXXIdexx Laboratories Inc11.66%-84.06%
CSTLCastle Biosciences Inc10.29%-85.94%
MTDMettler-Toledo International Inc9.87%-86.51%
MYNZMainz Biomed N.V.9.82%-86.58%
IQVIQVIA Holdings Inc9.14%-87.50%
RDNTRadnet Inc8.38%-88.54%
IMDXInsight Molecular Diagnostics Inc7.62%-89.59%
ILMNIllumina Inc5.98%-91.82%
AAgilent Technologies Inc5.87%-91.98%
GHGuardant Health Inc5.67%-92.25%
NTRANatera Inc3.35%-95.42%
TWSTTwist Bioscience Corp2.84%-96.12%
BDSXBiodesix Inc2.43%-96.67%
SHCSotera Health Company2.32%-96.83%
QGENQiagen NV2.21%-96.99%